版本:
中国

BRIEF-CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting

Nov 21 CTi Biopharma Corp

* CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐